Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor

Area of Science:

• Nephrology
• Endocrinology
• Cardiology

Background:

• Metabolic syndrome (MetS), a cluster of conditions including hypertension, hyperglycemia/insulin resistance, hyperlipidemia, and abdominal obesity, is linked to increased cardiovascular events and mortality.
• MetS is an independent risk factor for chronic kidney disease (CKD), potentially causing or accelerating kidney disease progression.
• A bidirectional relationship exists between MetS and CKD; patients with CKD or kidney transplants have a higher prevalence of MetS.

Purpose of the Study:

• To review the mechanisms by which MetS affects CKD patients.
• To examine the impact of MetS in CKD on target organs (kidney, heart, brain, blood vessels).
• To outline treatment and prevention strategies for CKD combined with MetS.

Main Methods:

• Literature review of studies examining MetS and CKD.
• Analysis of mechanisms including glucose/lipid metabolism disorders, insulin resistance, hypertension, and medication effects (glucocorticoids, calcineurin inhibitors).
• Evaluation of MetS's effects on major organs in CKD patients.

Main Results:

• Kidney injury can lead to glucose and lipid metabolism disorders, insulin resistance, and hypertension, contributing to MetS.
• MetS exacerbates CKD progression and affects cardiovascular, cerebral, and vascular health.
• Medications used in CKD management, such as glucocorticoids and calcineurin inhibitors, can contribute to MetS development.

Conclusions:

• Understanding the intricate mechanisms linking MetS and CKD is crucial for effective management.
• Integrated strategies for diagnosis, treatment, and prevention are needed for CKD patients with MetS.
• Addressing MetS in CKD patients can mitigate risks to kidney function and overall cardiovascular health.